Associations between performance on the Latin American Version of the Face‐Name and plasma Neurofilament Light Chain, NfL, in individuals with autosomal‐dominant Alzheimer’s disease: Preliminary findings from the Colombia‐Boston ‐COLBOS‐ remote study

We previously reported that performance on the Latin American Spanish version of the Face‐Name Associative Memory Exam (LAS‐FNAME) differentiated between cognitively intact Presenilin1 (PSEN1) E280A mutation carriers from non‐carriers and that this performance was also associated with greater amyloid and tau burden in the entorhinal and inferior temporal cortices, when examining all carriers. Neurofilament light chain (NfL), a plasma‐based biomarker for neurodegeneration and a promising marker for early Alzheimer’s disease (AD) detection, is less invasive and expensive than PET imaging. Here, we examined whether levels of plasma NfL were associated with LAS‐FNAME performance in non‐demented PSEN1‐E280A carriers and non‐carriers.